|1.||Sporn, Michael B: 8 articles (11/2010 - 10/2002)|
|2.||Risingsong, Renee: 7 articles (11/2010 - 10/2002)|
|3.||Williams, Charlotte R: 7 articles (11/2010 - 10/2002)|
|4.||Royce, Darlene B: 6 articles (11/2010 - 05/2004)|
|5.||Liby, Karen: 5 articles (12/2009 - 05/2004)|
|6.||Lamph, William W: 5 articles (07/2008 - 10/2002)|
|7.||Heyman, Richard A: 4 articles (02/2006 - 10/2002)|
|8.||Yore, Mark M: 3 articles (12/2009 - 05/2008)|
|9.||Suh, Nanjoo: 3 articles (10/2006 - 10/2002)|
|10.||Ogilvie, Kathleen M: 3 articles (02/2006 - 08/2002)|
07/01/2006 - "The rexinoids LG100268 and bexarotene (LG1069, Targretin) were highly efficacious in the prevention of neu-induced mammary carcinomas. "
05/15/2004 - "We show that the selective estrogen receptor modulator arzoxifene (Arz) and the rexinoid LG100268 (268) synergize to promote apoptosis in a rat model of estrogen receptor-positive breast carcinoma and in estrogen receptor-positive human breast cancer cells in culture. "
10/15/2007 - "Long-term treatment with LG100268 significantly prevented invasive mammary tumor development. "
07/01/2006 - "Dietary LG100268 at 100 mg/kg diet decreased tumor multiplicity by 32% (P = 0.0114) in intact rats and 50% (P < 0.0001) in ovariectomized rats. "
10/01/2012 - "By 60 weeks of age, vehicle-treated mice developed tumors in 52% of transplanted mammary glands, whereas mice treated with tamoxifen and LG100268 developed tumors in only 13% of transplanted mammary glands. "
10/01/2012 - "The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice."
10/15/2007 - "The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice."
|3.||Breast Neoplasms (Breast Cancer)
10/15/2007 - "For invasive breast cancer prevention, MMTV-erbB2 mice were treated with daily gastric gavage of vehicle, LG100268 (10 mg/kg), or LG100268 (100 mg/kg) for long term starting at 3 months of age. "
10/01/2012 - "On the basis of the hypothesis, rexinoid LG100268 plus tamoxifen would more effectively prevent the development of both ER-positive and ER-negative breast cancer. "
10/01/2002 - "The possible clinical use of the combination of arzoxifene and LG 100268 for prevention of breast cancer in women at high risk, for treatment of women in the adjuvant setting, or for treatment of end-stage disease should now be considered."
10/01/2002 - "Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268."
05/15/2004 - "The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer."
|5.||Body Weight (Weight, Body)
12/01/2000 - "Long-term (2 weeks) oral treatment with the rexinoids LG100268 and LG100324 reduced food intake and body weight gain, whereas rosiglitazone (BRL49653) tended to increase both food intake and weight gain. "
02/01/2004 - "LG100268 (LG268)] decreases both body weight gain (BWG) and food consumption (FC) in obese, insulin-resistant rodents. "
08/01/2000 - "Chronic administration of retinoid X receptor agonists LG 100268 and LG 100324 to Zucker fa/fa rats reduces food intake and body weight gain, lowers plasma insulin concentrations while maintaining normoglycaemia, indicating an improvement of insulin sensitivity."
|3.||Retinoid X Receptors (Retinoid X Receptor)
|6.||Retinoic Acid Receptors (Retinoic Acid Receptor)
|8.||Calcitriol Receptors (Calcitriol Receptor)
|9.||Cholecalciferol (Vitamin D3)
|10.||2- cyano- 3,12- dioxooleana- 1,9(11)- dien- 28- oic acid ethyl amide